http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140133241-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate | 2013-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_939d1dc710f3f2242641e6356109dfca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f59624fd56081f7a01429a1834f5aee |
| publicationDate | 2014-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20140133241-A |
| titleOfInvention | Pharmaceutical Composition for Preventing or Treating Autophagy-associated Diseases, Apoptosis-associated Diseases, Hyperproliferative Disease or Angiogenic Diseases |
| abstract | (A) a pharmaceutical effective amount of convalatoxin, a convalatoxin derivative or a pharmaceutically acceptable salt thereof; And (b) a pharmaceutical composition for preventing or treating autophage-related diseases, apoptosis-related diseases, hyperproliferative diseases or angiogenesis diseases comprising a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention simultaneously induce autophagy and apoptosis of cells in a dose-dependent and dose-time-dependent manner, thus inhibiting the hyperproliferation and angiogenesis of the cells in a dose-dependent manner, , Apoptosis-related diseases, hypertrophic diseases or angiogenic diseases. Further, by confirming that the pharmaceutical composition of the present invention induces autophagy by increasing phosphorylation of AMP-activated protein kinase (AMPK) and reducing phosphorylation of mTOR and p70S6K, the autophagy induction mechanism of the pharmaceutical composition of the present invention It contributes to revealing. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018012769-A1 |
| priorityDate | 2013-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 152.